Today, the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,064,403, which relates to compositions and methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer previously treated with an anti-estrogen receptor, anti-progesterone receptor, or an anti-her2 drug. Dr. Carlton D. Donald, President and CEO of PHIGENIX, commented, “We are extremely pleased to receive this new patent as we continue to innovate new drugs for patients with hard-to-treat cancers.”